Estrogen-Receptor Antagonists for Treatment and Re-Sensitization of Anti-Estrogen Resistant Breast Cancers
Categories: “Cancer Therapeutics“
Reference #: 2012-003
Resistance to anti-estrogenic therapies remains as a very significant problem in the treatment of breast cancer. The present invention describes small molecules for the treatment or prevention of breast cancer. These compounds are effective against anti-estrogen resistant cells, and most remarkably, restore the sensitivity of Tamoxifen and Fulvestrant-resistant cells to Tamoxifen and Fulvestrant.
Potential treatment or prevention of breast cancers, endometrial cancers, and other cancers.
- Potential therapeutic for anti-estrogen resistant cancers
- Can restore sensitivity to Tamoxifen and Fulvestrant
- Can be used alone or in conjunction with Tamoxifen
Stage of Development
Researchers have identified compounds that inhibit ER-α activity in multiple cell lines. Mechanism of action studies have been completed.
Manuscript is in preparation
Patent application filed.